Eli Lilly and Company (LLY)
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.
Lilly says Mounjaro and Zepbound contributed to big revenue boost
Lilly's CEO says that the company has “tremendous momentum” entering 2025.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
Eli Lilly Stock Rises After Earnings Beat
Fourth-quarter adjusted earnings of $5.32 a share beat analysts' estimates of $5.01.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply for Eli Lilly's incretin drugs, such as Zepbound and Mounjaro, over the last year.
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Eli Lilly and Company LLY will release its fourth-quarter financial results, before the opening bell, on Thursday, Feb. 6, 2025.
Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?
Eli Lilly And Co LLY will be reporting its fourth-quarter earnings on Thursday. Wall Street expects $4.94 in EPS and $13.66 billion in revenues as the company reports before market hours.
Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
